JMP Securities Transfers Coverage on Incyte (INCY), Upgrades to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to JMP Securities Transfers Coverage on Incyte (INCY), Upgrades to Market Outperform
September 5, 2019 3:37 AM EDT
Morgan Stanley analyst Matthew Harrison assumes coverage on Incyte (NASDAQ: INCY) with a Equalweight rating and a price target of $87.00 (from $82.00).
For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.
Shares of Incyte closed at $77.62 yesterday.
...
More
September 5, 2019 3:28 AM EDT
Oppenheimer analyst Jay Olson upgraded Incyte (NASDAQ: INCY) from Perform to Outperform with a price target of $100.00.
The analyst comments "We upgrade INCY to Outperform based on attractive valuation for a company with increasing revenues, accelerating cash flows and a maturing... More
September 3, 2019 8:14 AM EDT
Incyte (Nasdaq: INCY) announces that abstracts highlighting data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain from September 27-October 1, 2019.
Results from FIGHT-202, a Phase 2 study of pemigatinib as a second-line treatment for patients with advanced/metastatic or surgically unresectable cholangiocarcinoma, including updated safety and efficacy data in patients with FGFR2 fusions or rearrangements, as well as genomic profiling and correlations with clinical outcomes will be presented. Results from the Phase 1... More
